Etsy exploded 88% out of the gate, giving it the best first-day return for a tech IPO in over a year. Cancer immunotherapy biotech Aduro Biotech flew up 147%, the year's third IPO to more than double on day one.
This past week was the second largest of 2015...read more
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, raised $76 million by offering 4 million shares at $19, within the range of $18 to $20. The IPO was being marketed by WR Hambrecht on a "best efforts"...read more
As many as seven IPOs could price this week, and four have a proposed market cap over $1 billion. So far, only eight companies that large have gone public this year, or 22% of all...read more
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, announced terms for its IPO on Tuesday. The IPO is being marketed by WR Hambrecht on a "best efforts" basis. The Austin, TX-based company plans to raise $76...read more
US IPO Weekly Recap: 7 IPOs see Etsy vault 70%, proving vintage is in vogue
Etsy exploded 88% out of the gate, giving it the best first-day return for a tech IPO in over a year. Cancer immunotherapy biotech Aduro Biotech flew up 147%, the year's third IPO to more than double on day one. This past week was the second largest of 2015...read more
Colorectal cancer biotech Xbiotech prices $76 million IPO at $19 midpoint
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, raised $76 million by offering 4 million shares at $19, within the range of $18 to $20. The IPO was being marketed by WR Hambrecht on a "best efforts"...read more
Week ahead: Crafts, cancer cures and cash flow in a week with 7 IPOs including Party City
As many as seven IPOs could price this week, and four have a proposed market cap over $1 billion. So far, only eight companies that large have gone public this year, or 22% of all...read more
Anitbody biotech Xbiotech sets terms for $76 million IPO
Xbiotech, which is developing antibodies for colorectal cancer and various other conditions, announced terms for its IPO on Tuesday. The IPO is being marketed by WR Hambrecht on a "best efforts" basis. The Austin, TX-based company plans to raise $76...read more